🇺🇸·Aug 21Research
NCT07198074: Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Study type: INTERVENTIONAL. Phase: PHASE3.
Publisher
C
ClinicalTrials.gov
USA
This page provides a limited summary, publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- ClinicalTrials.gov
- Region
- USA
- Scope
- Research
- Published
- August 21, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Study type: INTERVENTIONAL. Phase: PHASE3.
Source route
Continue on clinicaltrials.gov
Leave the platform to read the original full article on the publisher site.
Source: ClinicalTrials.gov
Scope: Research
Related coverage
More related coverage
Crossref/14h ago
Evaluating the Clinical Use of Cefoperazone/ Sulbactam and Post-discharge Antibiotics Practices in Infectious Diseases Patients
Crossref/14h ago
Polycystic Ovary Syndrome (PCOS) -Associated Infertility: Clinical Insights and Emerging Deep Learning Approaches for Early Detection and Prediction
Crossref/14h ago
Low-Dose Silodosin for Premature Ejaculation: A Clinical Evaluation
Crossref/14h ago